Zobrazeno 1 - 8
of 8
pro vyhledávání: ''
Autor:
Michael Ghadimi, Ethan B. Ludmir, Ralf Hofheinz, Emmanouil Fokas, Bruce D. Minsky, Claus Rödel, Markus Diefenhardt
Publikováno v:
JAMA Oncology. 6:1416
Importance Despite numerous published phase 3 trials, the association of treatment adherence with outcomes for patients with rectal cancer remains largely unexplored. Objective To analyze the association of treatment adherence with disease-free survi
Publikováno v:
JAMA Network Open
Key Points Question Is peer influence associated with physician adoption of new cancer therapies? Findings In this cohort study of 44 012 Medicare beneficiaries with cancer treated by 3261 oncologists, use of bevacizumab in 2007 to 2010 was greater a
Autor:
Michael J. Englesbe, Sunil Agarwal, Jay S. Lee, Chad M. Brummett, Kao-Ping Chua, Jennifer F. Waljee, Hsou Mei Hu, John D. Bryan, Rebecca L. Haffajee
Publikováno v:
JAMA Network Open
Key Points Question What is the association of opioid prescribing duration limits with postoperative opioid prescribing in Massachusetts and Connecticut? Findings This interrupted time series analysis and cross-sectional study of 16 281 opioid-naive
Publikováno v:
JAMA Network Open
Aspirin use has been associated with reduced risk of cancer mortality, particularly of the colorectum. However, aspirin efficacy may be influenced by biological characteristics, such as obesity and age. With the increasing prevalence of obesity and c
Autor:
Colleen M. Brensinger, Craig Newcomb, Hannah Wunsch, Mark D. Neuman, Duminda N. Wijeysundera, Karim S. Ladha, Tobias Svensson, Max Bell, Lakisha J. Gaskins, Brian T. Bateman, Gabriella Bröms, Jennifer Bethell, Linn Hallqvist
Publikováno v:
JAMA Network Open. 2:e1910734
Small studies and anecdotal evidence suggest marked differences in the use of opioids after surgery internationally; however, this has not been evaluated systematically across populations receiving similar procedures in different countries.To determi
Autor:
Thierry Conroy, Eric Francois, Gael Deplanque, François Ghiringhelli, Christian Borel, Sandrine Hiret, Jean-François Seitz, Olivier Bouché, Trevor Stanbury, Jaafar Bennouna, Antoine Adenis, Aurélie Bertaut, Marc G. Denis, Mohamed Hebbar, Christophe Borg, Pascal Artru, Gaetan Des Guetz
Publikováno v:
JAMA Oncology. 5:83
IMPORTANCE: Second-line treatment with chemotherapy plus bevacizumab or cetuximab is a valid option for metastatic colorectal cancer. OBJECTIVE: To evaluate the progression-free survival (PFS) rate at 4 months with chemotherapy plus bevacizumab vs ce
Autor:
Andrea M. Austin, Gabriel A. Brooks, Anna N. A. Tosteson, Deborah Schrag, Hajime Uno, Konstantin H. Dragnev
Publikováno v:
JAMA Network Open
Key Points Question Does the risk of hospitalization among elderly patients receiving chemotherapy for metastatic, nonsquamous, non–small cell lung cancer vary by chemotherapy regimen? Findings In a cohort study of 2182 propensity-matched Medicare
Autor:
Henrik Lindman, Päivi Auvinen, Greger Nilsson, Riikka Huovinen, Minna Tanner, Vesa Kataja, Johan Ahlgren, Sanna Kosonen, Outi Lahdenperä, Pirkko-Liisa Kellokumpu-Lehtinen, Petri Bono, Kenneth Villman, Heikki Joensuu, Paula Poikonen-Saksela, R. Kokko, Arja Jukkola-Vuorinen, Paul Nyandoto, Jouni Junnila
Publikováno v:
JAMA Oncology. 3:793
Importance Capecitabine is not considered a standard agent in the adjuvant treatment of early breast cancer. The results of this study suggest that addition of adjuvant capecitabine to a regimen that contains docetaxel, epirubicin, and cyclophosphami